KALA BIO
KALA
KALA BIO (KALA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$85.50
- EPS estimate
- −$85.17
- EPS surprise
- −0.39%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 8, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 8, 2025 | −$85.17 | −$85.50 | −0.39% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$101.50 | −$70.50 | +30.54% | $0.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$114.00 | −$87.00 | +23.68% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$121.50 | −$96.50 | +20.58% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$220.25 | −$158.00 | +28.26% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$144.50 | −$210.00 | −45.33% | $0.00 | SEC |
| Q4 2023 | Mar 29, 2024 | −$181.00 | −$159.00 | +12.15% | $0.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$149.00 | −$170.50 | −14.43% | $0.00 | SEC |
| Q2 2023 | Aug 4, 2023 | −$159.33 | −$218.00 | −36.82% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$242.33 | −$349.50 | −44.22% | $0.00 | SEC |
| Q4 2022 | Mar 3, 2023 | −$327.75 | −$398.50 | −21.59% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | $537.50 | $962.50 | +79.07% | $420,000.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$1,087.50 | −$950.00 | +12.64% | $2.1M | SEC |
| Q1 2022 | May 16, 2022 | −$841.08 | −$1,125.00 | −33.76% | $1.4M | SEC |
| Q4 2021 | Mar 29, 2022 | −$982.94 | −$1,700.00 | −72.95% | $1.9M | SEC |
| Q3 2021 | Nov 15, 2021 | −$1,175.00 | −$1,075.00 | +8.51% | $3.1M | SEC |
| Q2 2021 | Aug 5, 2021 | −$1,075.15 | −$1,425.00 | −32.54% | $3.1M | SEC |
| Q1 2021 | May 5, 2021 | −$1,183.16 | −$1,225.00 | −3.54% | $3.3M | SEC |
| Q4 2020 | Feb 25, 2021 | −$1,205.95 | −$1,375.00 | −14.02% | $2.2M | SEC |
| Q3 2020 | Nov 5, 2020 | −$1,082.38 | −$1,250.00 | −15.49% | $2.2M | SEC |
Quarterly revenue
Frequently asked questions
When did KALA BIO (KALA) last report earnings?
KALA BIO last reported on Aug 8, 2025, covering fiscal Q2 2025.
Did KALA beat earnings estimates?
No. KALA BIO reported EPS of −$85.50 for Q2 2025 against a −$85.17 estimate — a 0.39% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.